Cargando…

Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data

BACKGROUND: The effect of combination of fibrate with statin on major adverse cardiovascular events (MACE) following acute coronary syndrome (ACS) hospitalization is unclear. The main aim of this study was to investigate the 30-day rate of MACE in patients who participated in the nationwide ACS Isra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tenenbaum, Alexander, Medvedofsky, Diego, Fisman, Enrique Z., Bubyr, Liudmila, Matetzky, Shlomi, Tanne, David, Klempfner, Robert, Shemesh, Joseph, Goldenberg, Ilan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327654/ https://www.ncbi.nlm.nih.gov/pubmed/22523582 http://dx.doi.org/10.1371/journal.pone.0035298

Ejemplares similares

Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
por: Tenenbaum, Alexander, et al.
Publicado: (2004)

Statins research unfinished saga: desirability versus feasibility
por: Fisman, Enrique Z, et al.
Publicado: (2005)

Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review
por: Mozetic, Vania, et al.
Publicado: (2017)

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
por: Klempfner, Robert, et al.
Publicado: (2012)

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
por: Mayne, Janice, et al.
Publicado: (2008)

Statins and/or fibrates for diabetic retinopathy: a systematic review and meta-analysis
por: Mozetic, Vânia, et al.
Publicado: (2019)

Comparative efficacy and safety of statin and fibrate monotherapy: A systematic review and meta-analysis of head-to-head randomized controlled trials
por: Blais, Joseph E., et al.
Publicado: (2021)

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)
por: Leibovitz, Eyal, et al.
Publicado: (2013)

Update on the use of fibrates: focus on bezafibrate
por: Goldenberg, Ilan, et al.
Publicado: (2008)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
por: Tenenbaum, Alexander, et al.
Publicado: (2006)

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
por: Moutzouri, Elisavet, et al.
Publicado: (2010)

Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
por: Tenenbaum, Alexander, et al.
Publicado: (2008)

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
por: Alagona, Peter
Publicado: (2010)

Statins, fibrates, thiazolidinediones and resveratrol as adjunctive therapies in sepsis: could mitochondria be a common target?
por: Morel, Jerome, et al.
Publicado: (2014)

Elucidating the Effects of the Lipids Regulators Fibrates and Statins on the Health Status of Finfish Species: A Review
por: Blonç, Manuel, et al.
Publicado: (2023)

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
por: Arbel, Yaron, et al.
Publicado: (2016)

Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study
por: Chan, Sammy Y, et al.
Publicado: (2008)

Reporting quality and adherence of randomized controlled trials about statins and/or fibrates for diabetic retinopathy to the CONSORT checklist
por: Mozetic, Vânia, et al.
Publicado: (2019)

Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy
por: Lee, Jun-beom, et al.
Publicado: (2017)

Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2021)

Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry
por: Steiner, Hillel, et al.
Publicado: (2016)

Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease
por: Younis, Arwa, et al.
Publicado: (2016)

The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome
por: Li, Xiang-ping, et al.
Publicado: (2013)

Comparison of pleiotropic effects of statins vs fibrates on laboratory parameters in patients with dyslipidemia: A retrospective cohort study
por: Takeuchi, Satoshi, et al.
Publicado: (2020)

Ascorbic Acid Significantly Decreases Creatine Kinase Plasma Levels in an Animal Model of Statin/Fibrate-Induced Myopathy
por: Zabihi, Mohsen, et al.
Publicado: (2021)

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
por: Tenenbaum, Alexander, et al.
Publicado: (2014)

The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study
por: Younis, Arwa, et al.
Publicado: (2017)

SUN-071 Unexpected Paradoxical Extremely Low of HDL-Cholesterol Level in a Non-Diabetes, Non-CKD Patient after Treatment with Specific Fibrate and Statin and Specific Fibrate Alone
por: Kiatpanabhikul, Phatharaporn
Publicado: (2019)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Statin Monotherapy and Statin plus Ezetimibe Combination in a Real-World Setting
por: Ezhov, Marat V., et al.
Publicado: (2023)

The efficacy of Ezetimibe added to ongoing Fibrate-Statin therapy on postprandial lipid profile in the patients with type 2 Diabetes mellitus
por: Sharifi, Faranak, et al.
Publicado: (2013)

Effect and safety of combination lipid‐lowering therapies based on statin treatment versus statin monotherapies on patients with high risk of cardiovascular events
por: Wang, Chunli, et al.
Publicado: (2018)

Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients
por: Abramson, Beth L, et al.
Publicado: (2011)

Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis
por: Bae, Jaehyun, et al.
Publicado: (2020)

Confirmation of Statin and Fibrate Use from Small-Volume Archived Plasma Samples by High-Throughput LC-MS/MS Method
por: Kusovschi, Jennifer D., et al.
Publicado: (2023)

Treatment of Statin-Induced Necrotizing Autoimmune Myopathy With Glucocorticoid Monotherapy
por: Lempel, Matthew, et al.
Publicado: (2020)

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
por: Chapman, M. John, et al.
Publicado: (2010)

The Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Evacetrapib Administered as Monotherapy or in Combination With Statins
por: Friedrich, S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mag0o76l1kpfrod4iiohrfso9t